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Galectin-1 (Gal-1), an evolutionarily conserved β-galactoside-binding lectin, controls immune cell homeostasis and tempers acute
and chronic inflammation by blunting proinflammatory cytokine synthesis, engaging T-cell apoptotic programs, promoting
expansion of T regulatory (Treg) cells, and deactivating antigen-presenting cells. In addition, this lectin promotes angiogenesis
by co-opting the vascular endothelial growth factor receptor (VEGFR) 2 signaling pathway. Since a coordinated network of
immunomodulatory and proangiogenic mediators controls cardiac homeostasis, this lectin has been proposed to play a key
hierarchical role in cardiac pathophysiology via glycan-dependent regulation of inflammatory responses. Here, we discuss the
emerging roles of Gal-1 in cardiovascular diseases including acute myocardial infarction, heart failure, Chagas cardiomyopathy,
pulmonary hypertension, and ischemic stroke, highlighting underlying anti-inflammatory mechanisms and therapeutic
opportunities. Whereas Gal-1 administration emerges as a potential novel treatment option in acute myocardial infarction and
ischemic stroke, Gal-1 blockade may contribute to attenuate pulmonary arterial hypertension.
1. Introduction
Galectins are a family of β-galactoside-binding lectins widely
expressed in a variety of cells and tissues [1]. These animal
lectins play critical roles in the regulation of both innate
and adaptive immunity, inflammation, wound healing, and
angiogenesis [2–6]. To date, 15 different members have been
identified, which are classified according to their biochemical
structure into three groups: (a) prototype galectins, including
galectin- (Gal-) 1, -2, -5, -7, 10, -11, -13, -14, and -15, display
one carbohydrate-recognition domain (CRD) and can
dimerize; (b) tandem-repeat galectins, including Gal-4, -6,
-8, -9, and -12, exhibit two CRDs associated with a linker
peptide; and (c) the unique chimera-type Gal-3 contains
one CRD and an additional nonlectin domain and can oligo-
merize [1]. Emerging evidence demonstrates that galectins
play important roles in cardiovascular pathophysiology by
controlling acute and chronic inflammatory responses [7].
Despite structural similarities, individual members of the
galectin family play distinct roles during inflammatory pro-
cesses by controlling innate and adaptive immune compart-
ments [8]. This includes modulation of proinflammatory
Hindawi
Mediators of Inflammation
Volume 2018, Article ID 8696543, 11 pages
https://doi.org/10.1155/2018/8696543
cytokine production, promotion of T regulatory (Treg) cell
expansion, and control of immune cell differentiation and
survival [9].
1.1. Galectin-1 (Gal-1). Gal-1, the first galectin identified,
functions mostly as an anti-inflammatory mediator that
represses innate and adaptive immune programs [1, 9].
Expression of Gal-1 is prominent in inflammatory macro-
phages [10, 11], activated T lymphocytes [12], Treg cells
[13], and tolerogenic dendritic cells [14]. From a structural
viewpoint, Gal-1 consists of two subunits of 14.5 kDa (135
amino acids) present in a dynamic dimerization equilibrium
[15]. Because of an unusual number of six cysteine residues,
this lectin is highly susceptible to oxidative inactivation,
which hampers its immunoregulatory activity [16]. Gal-1
binds to multiple galactose-β1-4-N-acetyl-glucosamine (N-
acetyl-lactosamine; LacNAc) units present on the branches
of N- or O-linked glycans on a variety of cell surface recep-
tors and modulates their segregation, endocytosis, and sig-
naling [4, 15]. These glycan structures are generated by the
coordinated action of a set of glycosyltransferases including
N-acetylglucosaminyltransferase 5 (MGAT5), an enzyme
that creates β1,6-N-acetylglucosamine-branched complex
N-glycans, and core-2 β1-6-N-acetylglucosaminyltransferase
1 (C2GNT1), an enzyme that catalyzes branching of core-2
O-glycan structures. Conversely, Gal-1 binding is prevented
when LacNAc is modified by α2,6-linked sialic acid incorpo-
rated by α2,6-sialyltransferase 1 (ST6GAL1) [3]. Gal-1 con-
trols biological processes through extracellular mechanisms
by cross-linking cell surface glycoconjugates or intracellu-
larly by influencing a variety of signaling events [1, 2].
Through glycosylation-dependent mechanisms, this lectin
modulates cellular activation, proliferation, migration, and
survival, playing a critical role in the resolution of acute
and chronic inflammation [4–6, 15]. In addition, Gal-1 pro-
motes neovascularization by signaling through vascular
endothelial growth factor receptor- (VEGFR-) 2 [17, 18].
Because of its prominent anti-inflammatory, proresolving,
and proangiogenic activities, Gal-1 has been proposed to be
a key mediator of cardiovascular homeostasis [19].
Here, we discuss the relevance of Gal-1 in cardiovascular
disorders including acute myocardial infarction (AMI), heart
failure (HF), Chagas cardiomyopathy, pulmonary hyperten-
sion (PAH), and ischemic stroke and highlight cellular and
molecular mechanisms underlying these effects.
1.2. Acute Myocardial Infarction. Acute myocardial infarc-
tion (AMI) is caused by a sudden interruption in blood oxy-
gen supply mostly due to atherothrombosis; this effect is
accompanied by a storm of proinflammatory cytokines and
a dysregulation of effector and regulatory immune cell mech-
anisms [20]. AMI is the leading cause of death worldwide,
and those who survive are at higher risk for adverse ventric-
ular remodeling and heart failure [21].
Gal-1 is expressed in the normal heart of many species
[22–24]. Cardiomyocytes constitutively express Gal-1 at the
cytosolic compartment in an organized striated pattern close
to sarcomeric actin but not myosin [23] (Figure 1(a)). How-
ever, Gal-1 expression is further upregulated during AMI,
with a peak as early as 20min after experimental coronary
artery ligation [24], followed by a second peak at 7 days
[19]. This bimodal expression pattern may reflect different
cells that express Gal-1 in AMI either ischemic cardiomyo-
cytes (20min) or leukocytes that promote resolution of
inflammation (7 days).
Cultured cardiomyocytes upregulate and secrete Gal-1
early after hypoxia and in response to proinflammatory cyto-
kines [19], as seen in the early phase of AMI in vivo
(Figure 1(a)). Whereas early upregulation of Gal-1 may serve
as a homeostatic safeguard mechanism to prevent a dysregu-
lated inflammatory response that could otherwise promote
adverse remodeling [20], augmented Gal-1 expression later
in the course of AMI could influence the resolution of cardiac
inflammation and restore homeostasis [25].
Interestingly, Gal-1 was found to be upregulated 7 days
after nonreperfused AMI, associated with a peak in infiltrat-
ing dendritic cells, lymphocytes, and macrophages [26].
Since Gal-1 promotes differentiation of tolerogenic dendritic
cells and M2-type macrophages [14, 27] which play protec-
tive roles in AMI [28, 29], Gal-1-glycan interactions may
contribute to reparative functions mediated by these cells.
Within the T-cell compartment, Gal-1 promotes apo-
ptosis of CD8 and Th1 and Th17 lymphocytes, promoting
a shift toward a Th2-dominant cytokine profile [3, 30, 31].
This effect is highly relevant in cardiovascular diseases as
upregulation of Th1 and Th17 cytokines is a typical hall-
mark observed in patients with acute coronary syndromes
[32–34] and is associated with adverse remodeling after
AMI [32]. On the other hand, healthy patients exhibiting
Th2-dominant responses may be protected from cardiovas-
cular disease [35]. Thus, Gal-1 emerges as an attractive ther-
apeutic candidate to limit innate and adaptive responses
early or late during cardiovascular inflammation. Remark-
ably, mice lacking Gal-1 (Lgals1−/−) showed adverse ventric-
ular remodeling after AMI with increased cardiac dilation
associated with dysregulated uncontrolled inflammation
(Table 1) [19]. Absence of Gal-1 led to an increase in car-
diac infiltration by T lymphocytes, macrophages, and natu-
ral killer (NK) cells, while anti-inflammatory Treg cells were
significantly reduced in this setting (Figure 1(b)) [19]. As
Treg cells are protective in AMI [36], and Gal-1 is also a
critical mediator of Treg function [13, 37], Gal-1-driven
inhibitory circuits may also operate in Treg-mediated pro-
tection during AMI.
As mentioned above, Gal-1 is expressed at the cytosolic
compartment of cardiomyocytes in association with actin
and is secreted in response to injury. Since Lgals1−/− mice
lack both the intracellular and extracellular Gal-1 activities,
it is difficult to infer which regulatory function of this lectin
controls adverse remodeling after AMI. However, treat-
ment with recombinant Gal-1 has been used to address
the extracellular versus intracellular roles of this lectin.
Mice treated with a single dose of recombinant Gal-1 dur-
ing AMI showed a significant improvement in ventricular
function and remodeling (Table 2) [19]. These effects sup-
port the concept that extracellular activities of Gal-1 prevail
in cardioprotection and highlight the therapeutic potential
of this lectin in patients with AMI. Interestingly, exogenous
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Figure 1: Role of Gal-1 in acute myocardial infarction. (a) Gal-1 is constitutively expressed in cardiomyocytes close to sarcomeric actin and is
increased and secreted after acute myocardial infarction (AMI), inflammation, and hypoxia. (b) Mice lacking Gal-1 (Lgals1−/−) show adverse
ventricular remodeling after AMI associated with increased inflammation and reduced proportion of regulatory T (Treg) cells.
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Gal-1 also prevented renal ischemia-reperfusion injury
through anti-inflammatory mechanisms [38]. Nevertheless,
as Gal-1 can be taken up by cells devoid of this lectin [39],
this alternative mechanism could also operate in cardiomyo-
cytes. Thus, in addition to the anti-inflammatory effects of the
exogenous protein, Gal-1-driven nonimmunological events
may also take place.
Atherosclerosis is the underlying pathology for most
AMIs. Atherosclerotic plaque rupture leads to coronary
thrombosis and myocardial necrosis. Inflammation plays a
key role in both development and fate of atherosclerosis
[40]. A recent large clinical study showed that inhibition of
atherosclerosis improved clinical outcomes in patients with
previous AMI [41]. Experimental atherosclerosis in ApoE−/
− mice fed with cholesterol showed increased Gal-1 expres-
sion in atherosclerotic plaques both in the media and in the
intima layer [42]. However, in broad contrast to Gal-3, Gal-
1 expression was not increased over time. Moreover, statin
treatment led to inhibition of Gal-3 but had no effect on
Gal-1 expression [42]. Although the role of Gal-1 in athero-
sclerosis has not yet been examined in detail, Gal-3 blockade
led to reduced atherosclerosis in ApoE−/− mice [43, 44].
1.3. Heart Failure. Patients who experience adverse ventricu-
lar remodeling after AMI are at increased risk of developing
heart failure (HF). Although mortality after AMI decreased
over the last decades, HF experienced a significant increase
[21]. HFmay also result from dilated nonischemic cardiomy-
opathy in the absence of AMI. The worldwide burden of HF
is increasing, representing a global health problem. Despite
advances in both pharmacological approaches and left ven-
tricle assisting devices, the only available treatment for
patients with end-stage HF is cardiac transplantation. Given
the role of Gal-1 as an important regulator of immune
responses, Gal-1 expression was investigated in patients with
advanced HF. Heart samples explanted from HF patients
undergoing transplantation showed increased Gal-1 expres-
sion compared to control hearts [19]. As expected, Gal-1
was localized within the inflammatory infiltrate and the inter-
stitium, but was also found in cardiomyocytes. Accordingly,
Gal-1 was upregulated in hearts from Chagas cardiomyopa-
thy patients [45]. Whether Gal-1 expression in the heart of
HF patients is part of the pathogenic mechanisms of the dis-
ease or may represent a compensatory effect in response to
enhanced inflammation is still not clear. Further studies in
patients with ischemic as well as nonischemic HF are war-
ranted to better understand the role of Gal-1 in both etiology
and prognosis of this disease. Moreover, as different environ-
mental factors may influence Gal-1 expression including
hypoxia, inflammation, aging, and metabolic status [3, 17],
further work is needed to dissect the role of these factors in
regulating the activity of this lectin.
Interestingly, mice lacking Gal-1 showed mild ventricular
dilation, reduced contractility, and an enhanced inflamma-
tory infiltrate composed of lymphocytes, macrophages, and
NK cells, as well as reduced number of Treg cells, indicative
of autoimmune myocarditis (Table 1) [19]. Moreover,
Lgals1−/− mice showed increased levels of circulating Th1
and Th17 cytokines [3] which might contribute to ventricu-
lar dysfunction and dilation, similar to the dysfunction
observed in septic patients [46], as well as experimental
inflammation induced by interleukin- (IL-) 1β and IL-18
[47, 48]. The upregulated expression of Gal-1 in patients with
HF may therefore represent a homeostatic mechanism that
controls autoimmune myocarditis in response to injury.
Whether intracellular Gal-1 participates in cardiomyocyte
contraction and may contribute to cardiomyopathy and HF
is still uncertain.
1.4. Chagas Disease. Chagas disease is caused by infection
with the protozoan parasite Trypanosoma cruzi (T. cruzi).
Acute infection is usually mild and undiagnosed; however,
20–30% of patients develop dilated cardiomyopathy several
years later [49]. Although the precise mechanisms underly-
ing Chagas cardiomyopathy are not completely understood,
they involve (a) injury to cardiomyocytes induced by T. cruzi,
(b) cardiac inflammation, (c) microvascular dysfunction, and
(d) autonomic disorders [50].
The T. cruzi parasite itself does not express Gal-1, but
anti-Gal-1 antibodies have been observed in patients with
Table 1: Preclinical models of cardiovascular disease in Lgals1−/− mice.
Model Effects Mechanisms Reference
AMI Worse remodeling Increased inflammation [19]
HF Spontaneous CMP Increased inflammation [19]
Chagas disease Reduced cardiac inflammation and parasite infection Not fully understood. Controversial results on survival [52, 54]
PAH Less PAH and reduced RV hypertrophy Decreased vasoreactivity [65]
AMI = acute myocardial infarction; HF = heart failure; PAH= pulmonary arterial hypertension; CMP = cardiomyopathy; RV = right ventricle.
Table 2: Effects of Gal-1 treatment on cardiovascular disease.
Model Effects Mechanisms Reference
AMI (reperfused) Improved remodeling Inflammation? (not evaluated) [19]
Stroke Improved sensorimotor dysfunction Increased neurogenesis. No effect on infarct volume [72]
AMI = acute myocardial infarction; HF = heart failure; PAH= pulmonary arterial hypertension.
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Chagas disease: whereas IgM and IgE antibodies raise with
acute infection, anti-Gal-1 IgG antibodies are present in the
chronic phase of the disease [45]. The source of this humoral
response was mainly associated to antigen release from host
cells, since no cross-reactivity was found between Gal-1 and
T cruzi proteins. Likewise, autoantibodies against other host
cell proteins have been observed in Chagas disease patients
[51]. In fact, serum Gal-1 increases in patients with Chagas
disease irrespective of cardiac involvement [52].
Infection with T. cruzi induces the release of interferon-γ
(IFN-γ), which promotes death of intracellular parasites,
thus limiting the extent of infection [50]. However, IFN-γ
and uncontrolled inflammationmay also lead to host damage
and myocarditis [53]. Thus, regulation of Gal-1 expression
by IFN-γ [19] may contribute as a homeostatic mechanism
to counterbalance cardiac inflammation. Whereas a study
found that Gal-1 binds weekly to T. cruzi with no direct effect
[54], another study showed no significant binding to the par-
asite [52]. On the contrary, Gal-1 appears to be upregulated
after infection and contributes to parasite-immune escape.
Activated B lymphocytes from infected mice secreted high
levels of Gal-1 which promoted apoptosis of activated T lym-
phocytes [55]. Moreover, infected dendritic cells also secreted
Gal-1 which contributed to expansion of the Treg cell com-
partment, leading to inhibition of CD8+ T-cells. These results
suggest that Gal-1 may limit the clearance of T. cruzi parasite
by triggering tolerogenic circuits [54]. However, the direct
effect of T. cruzi on cardiomyocytes involves different mech-
anisms. Whereas T cruzi infects cardiomyocytes and induces
apoptosis [56], infected cardiomyocytes may secrete Gal-1 as
a cardioprotectivemechanism, asGal-1 affinity to cardiomyo-
cytes prevents T. cruzi infection via glycosylation-dependent
mechanisms [52]. Whether this pathway involves inhibition
of T. cruzi binding to cardiomyocytes through hindrance of
glycan-binding sites remains uncertain. Interestingly, infected
cardiomyocytes show an altered glycophenotype which pre-
vents Gal-1 binding, promoting parasite escape [52]. Thus,
Gal-1 may control the fate and function of cardiomyocytes
through direct or indirect mechanisms involving immune-
dependent or independent pathways.
Despite the immunosuppressive effects of Gal-1, studies
in T. cruzi-infected Lgals1−/− mice showed reduced cardiac
inflammation [52] and lower myocardial parasite infiltration
(Table 1) [54]. Results on survival and parasitemia in those
mice were however controversial: as one study showed longer
survival despite increased parasitemia [52], another study
indicated reduced survival with similar parasitemia [54]. Dif-
ferences in these parameters may depend on the T. cruzi
strain: in vitro cardiomyocyte infection with Brazil, but not
Tulahuen strain of T. cruzi, showed an early mild reduction
of Gal-1 expression [52]. In this regard, in vivo infection with
T. cruzi Y strain showed higher cardiac inflammation and
mortality than the VFRA and Sc43 strains [57]. Thus, differ-
ent parasite strains may differentially affect Gal-1 expression,
selective binding to glycosylated receptors on host cells, and
clinical outcome of in vivo infection. Of note, all studies were
performed in T. cruzi-infected mice and may not fully reca-
pitulate the pathophysiology of Chagas cardiomyopathy,
which takes place several years after infection and may not
be associated with parasitemia or myocardial parasite infil-
tration. Finally, survival of these septic mice should not be
considered as a surrogate for Chagas cardiomyopathy.
Unfortunately, no animal models have completely recapitu-
lated the pathophysiology and clinical course of human Cha-
gas cardiomyopathy.
1.5. Pulmonary Arterial Hypertension. Pulmonary arterial
hypertension (PAH) is defined as a sustained increase in
mean pulmonary artery pressure in the absence of an eleva-
tion in pulmonary artery wedge pressure [58]. Symptoms
consist of dyspnea and right ventricle (RV) overload leading
to heart failure and death. The hallmark of PAH is prolifera-
tion of vascular smooth muscle cells (VSMCs) that cause
arterial narrowing leading to an increase in vascular resis-
tance [59]. However, endothelial cells (ECs) control VSMC
function, contraction, and proliferation through soluble
mediators, direct contact, and extracellular vesicles [60].
Gal-1 is expressed and secreted by both ECs and VSMCs.
This lectin modulates VSMC attachment, spreading, and
migration through affinity to extracellular matrix glycopro-
teins including laminin, fibronectin, and α1β1 integrin [61].
Both vascular deposits of laminin and fibronectin are typi-
cally observed in PAH [59, 62]. Interestingly, the precise
effects of Gal-1 on VSMC are controversial: whereas some
studies showed inhibition of spreading [60] and migration
[63], one study showed increased DNA replication following
exposure to this lectin [64].
Chronic hypobaric hypoxia, an established model of
PAH, leads to upregulation of lung Gal-1 expression [65].
Mice lacking Gal-1 showed reduced PAH in this model with
ameliorated RV hypertrophy (Table 1) [65]. Despite the
in vitro effects of Gal-1 on VSMCs, arterial muscularization
and microvessel density were not affected in Gal-1-deficient
mice. However, absence of Gal-1 in the lungs was associated
with decreased vasoreactivity after acute hypoxia, with no
effects in vasopressor response after 5-hydroxytryptamine
and potassium chloride [65]. Interestingly, effects on vascu-
lar reactivity could be associated to calcium influx in
VSMCs, since intracellular Gal-1 has been shown to inhibit
ICa,L modifying the Cav1.2 calcium channel in a splice
variant-dependent manner [66]. In this regard, Gal-1 pro-
motes Cav1.2 degradation in smooth muscle cells control-
ling vascular reactivity and blood pressure [67]. Moreover,
Gal-1 has also been implicated in the pathogenesis of pre-
eclampsia, which is characterized by hypertension and pro-
teinuria during pregnancy [68], suggesting new roles for
this lectin in pulmonary, systemic, and pregnancy-induced
arterial hypertension.
Remarkably, PAH increases RV afterload leading to con-
tractile dysfunction and Gal-1 expression in the normal heart
has been shown to be more pronounced in RV [24]. The con-
tribution of cardiomyopathy to the pathogenesis of PAH in
Gal-1-deficient mice warrants further consideration. More-
over, the phenotype of Lgals1−/− PAH mice appears to be
the combination of the absence of this lectin in the lung vas-
culature, the RV, and the contribution of the immune system.
Further experiments are warranted to investigate the transla-
tional and therapeutic implications of these findings.
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1.6. Stroke. Similar to AMI, stroke is characterized by a sud-
den drop in oxygen blood supply to the brain. In the normal
brain, Gal-1 is expressed by both neurons and glia [69, 70]
and modulate astrocyte function [71]. Gal-1 upregulation is
observed in vitro after anoxia [71] and in vivo in the infarcted
and penumbra area after experimental stroke [72]. Gal-1 has
been shown to induce astrocyte differentiation and brain-
derived neurotrophic factor (BDNF) secretion [71]. However,
Gal-1 treatment inhibited normal astrocyte proliferation
in vitro [73] and promoted microglial deactivation [27]. In
vivo, Gal-1 treatment promoted neurogenesis after stroke in
a carbohydrate-dependent manner, and antibody-mediated
Gal-1 blockade prevented this effect (Table 2) [72]. Similar
to Gal-1 treatment, transfer of stem cells overexpressing
Gal-1 significantly reduced infarct volume [74]. Stroke con-
fers an oxidative environment which inactivates Gal-1
impairing some carbohydrate-binding activities. However,
oxidized Gal-1 stimulates axonal regeneration [75]. Besides
its role in neuronal proliferation after injury, Gal-1 showed
a neuroprotective effect through inhibition of central nervous
system (CNS) inflammation. Interestingly, Gal-1 treatment
induced an M2 microglia phenotype, which prevented
inflammation-induced neurodegeneration [27]. On the con-
trary, an M1 “inflammatory” phenotype was associated with
CNS toxicity [76]. Gal-1 binds with higher affinity to M1
microglia skewing the balance toward an M2 phenotype
[27]. In addition, Gal-1 modifies the glutamate receptor
NMDA preventing binding of this neurotransmiter [77]. Fur-
thermore, this lectin participates in neuronal development,
since Lgals1−/− mice display altered olfactory neurons [78]
and reduced thermal sensitivity [79].
Serum Gal-1 levels have been evaluated in patients with
stroke. Whereas one study showed normal values of this pro-
tein [80], a larger cohort showed increased serum Gal-1 after
ischemic stroke [81]. Both studies, however, found no associ-
ation between Gal-1 levels and functional recovery. Thus,
serum Gal-1 does not appear to be a reliable biomarker of
local activation or neuroprotection.
1.7. Other Galectins. In addition to Gal-1, other members of
the galectin family may control cardiovascular pathophysi-
ology. Although their functions are beyond the scope of
the present review, we will briefly summarize their most
important contributions to cardiovascular diseases. Remark-
ably, Gal-3 has been widely studied in the context of cardio-
vascular disease and its effects and potential diagnostic and
prognostic values have been extensively reviewed elsewhere
[7, 8]. This “chimera-type” lectin is highly expressed by
macrophages, promoting inflammation, and fibrosis in vari-
ous organs [82]. In AMI, Gal-3 is upregulated early and
released to the extracellular compartment. Mice lacking
Gal-3 (Lgals3−/−) showed improved cardiac function and
reduced fibrosis after pressure overload and during hyperten-
sion [83]. On the contrary, adverse remodeling with
increased infarct size and reduced scar fibrosis was observed
in Lgals3−/−mice after AMI, probably due to ventricular rup-
ture [84]. Gal-3 promotes cardiac as well as renal, hepatic,
vascular, and pulmonary fibrosis [8, 85]. Several clinical stud-
ies reported increased serum levels of Gal-3 in cardiovascular
diseases, and this lectin is currently available as a cardiovas-
cular risk biomarker for heart failure [86]. Moreover, Gal-3
has been proposed as a biomarker that links oxidative stress
and inflammation in patients with atherothrombosis [87].
In addition, Gal-3 levels are also increased in patients with
AMI although the clinical value of this lectin is still a matter
of debate [8].
Although less studied, Gal-2 has also been shown to
play an important role in cardiovascular disease. Similar to
Gal-1, Gal-2 is a prototype lectin that promotes apoptosis
of activated CD8+ T cells [88, 89]. However, in contrast to
Gal-1, Gal-2 also showed proinflammatory activity within
the monocyte/macrophage compartment promoting a shift
towards an M1 phenotype [90] and inhibiting arteriogenesis
[91]. Interestingly, Gal-2 is elevated in atherosclerotic pla-
ques and colocalized with lymphotoxin-α [91, 92], suggesting
a galectin-cytokine interaction that favors proinflammma-
tory responses. Whereas a study in the Japanese population
showed a functional single-nucleotide polymorphism (SNP)
rs7291467 (C3279C➔T) in the Gal-2 gene (LGALS2) that
was associated with increased risk of AMI [92], these results
could not be confirmed in Caucasian individuals, and a meta-
analysis of seven studies showed no association between
LGALS2-C3279T and coronary artery disease [93].
Gal-9, a tandem-repeat member of the galectin family,
functionsmostly as an anti-inflammatory lectin [94] that pro-
motes Th1 and Th17 apoptosis through interaction with T-
cell immunoglobulin domain and mucin domain protein 3
(TIM-3) [2, 4]. Gal-9 has shown to prevent renal ischemia/
reperfusion injury, to attenuate experimental viral myocardi-
tis [95], and to improve survival after cardiac transplantation
[96]. Further studies are needed to unravel the precise roles of
Gal-9 in AMI and other cardiovascular diseases.
Finally, Gal-12, a tandem-repeat galectin preferentially
expressed in adipose tissue, contributes to differentiation
and turnover of preadipocytes [4, 97]. Targeted disruption
of Gal-12 gene (Lgals12) in mice increased insulin sensitivity
and glucose tolerance and contributed to diabetes and meta-
bolic syndrome [4, 97], suggesting the potential role of this
lectin in cardiovascular diseases.
Although a preferential set of receptors have been
described for individual members of the galectin family
[98], some glycosylated receptors may be shared by some
galectins. This includes CD45 which may be engaged by both
Gal-1 and Gal-3 on T lymphocytes [99] and VEGFR2 which
mediates the function of those galectins on ECs [18, 100].
Since different galectins may induce antagonic effects (e.g.,
proinflammatory versus anti-inflammatory effects), potential
cross-talk between these glycan-binding proteins and compe-
tition for similar receptors or glycan structures should also be
taken into consideration.
2. Conclusions
Galectins, a family of β-galactoside-binding lectins, have
emerged as key modulators of inflammatory processes
[1–4]. Gal-1, a highly conserved member of this family,
is widely expressed in different tissues and contributes to
immunosuppression in cancer, infection, and autoimmune
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diseases [1–4]. Recently, an emerging role for Gal-1 in car-
diovascular processes has been proposed (Figure 2). Gal-1
is constitutively expressed in cardiomyocytes complexed
with cytosolic actin. Interestingly, Gal-1 expression is
increased in the heart of patients with AMI, HF, and Chagas
cardiomyopathy. Mice lacking Gal-1 show increased suscep-
tibility to chronic inflammatory diseases and develop auto-
immune myocarditis and cardiac dysfunction, suggesting its
central nonredundant roles in cardiac homeostasis. Through
binding to cell surface ligands, Gal-1 not only controls innate
and adaptive immune programs that lead to resolution of
inflammatory responses, but also may control cardiomyocyte
survival leading to potential applications of this lectin in the
treatment of AMI and other cardiovascular disorders.
Accordingly, Gal-1 has been associated to the pathogenesis
of PAH and ischemic stroke (Figure 2). Further studies
should be aimed at defining specific roles of Gal-1 in the
heart, identifying its candidate receptors within cardiac tissue
and unveiling potential interplay with other members of the
galectin family, with the ultimate goal of designing and
implementing galectin-based therapies. Several strategies
have been proposed to modulate Gal-1 expression and func-
tion, including anti-Gal-1 antibodies in cancer and infection
settings [17, 101] as well as recombinant Gal-1 in autoim-
mune and chronic inflammatory disorders [3, 31]. From a
translational standpoint, recombinant Gal-1 administration
emerges as the most attractive approach for treatment of
cardiovascular diseases, particularly AMI [19]. On the other
hand, as Gal-1 cross-links and signals via glycosylated
receptors, an alternative strategy could potentially involve
modulation of glycans generated by the concerted action
of glycosyltransferases, including MGAT5, C2GNT1, and
ST6GAL1 [1]. Although mice lacking these glycosyltrans-
ferases display clear immunological phenotypes, there is
still no information on their role in cardiovascular inflam-
mation. Moreover, no studies have been performed to
evaluate the impact of glycosyltransferase inhibitors in
these pathologies. Although distinct Gal-1 receptors have
been identified on the surface of different cell types, includ-
ing CD45 and CD43 on T cells [99], CD45 on microglia
[27], and VEGFR2 on ECs [18], its potential counter-
receptors and glycosylated ligands on the surface of cardio-
myocytes have not yet been explored. Finally, further stud-
ies should be conducted to validate the above mentioned
mechanisms in clinical settings. Although animal models
represent an invaluable tool for understanding cardiovascu-
lar pathology, clinical studies are essential to definitely vali-
date galectin-driven circuits as patients may exhibit other
pathologic conditions which could also influence Gal-1
expression and function.
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